Literature DB >> 12054584

Phospholipase D2 stimulates cell protrusion in v-Src-transformed cells.

Yingjie Shen1, Yang Zheng, David A Foster.   

Abstract

Phospholipase D (PLD) activity has been implicated in several aspects of cell physiology including vesicle transport, signal transduction, cell proliferation, cytoskeletal structure, and oncogenic transformation. Two PLD isoforms (PLD1 and PLD2) have been identified and characterized. We have expressed both wild-type and catalytically inactive forms of PLD1 and PLD2 in 3Y1 rat fibroblasts and in 3Y1 cells transformed by v-Src, a tyrosine kinase that elevates PLD activity. The v-Src-transformed 3Y1 cells have small, but distinct cell protrusions, implicated in cell migration and metastasis. We report here that elevated expression of PLD2 substantially increased the length of the cell protrusions and that a catalytically inactive PLD2 mutant abolished the cell protrusions. The extended protrusions in the PLD2-overexpressing cells were dependent upon microtubule assembly. These data suggest a role for PLD2 in the v-Src-mediated formation of cell protrusions that may be critical for the invasive properties of v-Src-transformed cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054584     DOI: 10.1016/S0006-291X(02)00204-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Association of lipid metabolism with ovarian cancer.

Authors:  M Tania; M A Khan; Y Song
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

Review 2.  The exquisite regulation of PLD2 by a wealth of interacting proteins: S6K, Grb2, Sos, WASp and Rac2 (and a surprise discovery: PLD2 is a GEF).

Authors:  Julian Gomez-Cambronero
Journal:  Cell Signal       Date:  2011-06-29       Impact factor: 4.315

3.  Serum deprivation confers the MDA-MB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion.

Authors:  Qing Ye; Samuel Kantonen; Julian Gomez-Cambronero
Journal:  J Mol Biol       Date:  2012-12-10       Impact factor: 5.469

4.  Requirement of phospholipase D1 activity in H-RasV12-induced transformation.

Authors:  F Gregory Buchanan; Matt McReynolds; Anthony Couvillon; Yoonseok Kam; Vijaykumar R Holla; Raymond N Dubois; John H Exton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-24       Impact factor: 11.205

Review 5.  Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis.

Authors:  Wenjuan Su; Qin Chen; Michael A Frohman
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

6.  Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: targeting and incapacitating cancer cells.

Authors:  Xin Chen; Li Hui; David A Foster; Charles Michael Drain
Journal:  Biochemistry       Date:  2004-08-31       Impact factor: 3.162

Review 7.  Phospholipase signalling networks in cancer.

Authors:  Jong Bae Park; Chang Sup Lee; Jin-Hyeok Jang; Jaewang Ghim; Youn-Jae Kim; Sungyoung You; Daehee Hwang; Pann-Ghill Suh; Sung Ho Ryu
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

8.  Phospholipase D activity regulates integrin-mediated cell spreading and migration by inducing GTP-Rac translocation to the plasma membrane.

Authors:  Young Chan Chae; Jung Hwan Kim; Kyung Lock Kim; Hyun Wook Kim; Hye Young Lee; Won Do Heo; Tobias Meyer; Pann-Ghill Suh; Sung Ho Ryu
Journal:  Mol Biol Cell       Date:  2008-05-14       Impact factor: 4.138

9.  Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.

Authors:  Sarah A Scott; Paige E Selvy; Jason R Buck; Hyekyung P Cho; Tracy L Criswell; Ashley L Thomas; Michelle D Armstrong; Carlos L Arteaga; Craig W Lindsley; H Alex Brown
Journal:  Nat Chem Biol       Date:  2009-01-11       Impact factor: 15.040

Review 10.  Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.

Authors:  Ronald C Bruntz; Craig W Lindsley; H Alex Brown
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.